Cost–Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels

To evaluate the cost–utility of pembrolizumab versus chemotherapy as the first-line setting for metastatic non-small cell lung cancer (NSCLC) from the US health care system perspective, a Markov model was developed to compare the lifetime cost and effectiveness of pembrolizumab versus chemotherapy f...

Descripción completa

Detalles Bibliográficos
Autores principales: Weng, Xiuhua, Luo, Shaohong, Lin, Shen, Zhong, Lixian, Li, Meiyue, Xin, Rao, Huang, Pinfang, Xu, Xiongwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851532/
https://www.ncbi.nlm.nih.gov/pubmed/31610828
http://dx.doi.org/10.3727/096504019X15707883083132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851532/
https://www.ncbi.nlm.nih.gov/pubmed/31610828
http://dx.doi.org/10.3727/096504019X15707883083132

Ejemplares similares